Zobrazeno 21 - 30
of 45
pro vyhledávání: '"Fanny Bouquet"'
Autor:
Sarah Giacometti, Bruno Lacarelle, Ariel Savina, Manon Carré, Bertrand Pourroy, Fanny Bouquet, Anne Rodallec, Guillaume Sicard, Raphaelle Fanciullino, Joseph Ciccolini
Publikováno v:
International Journal of Nanomedicine
International Journal of Nanomedicine, Dove Medical Press, 2018, 13, pp.6677-6688. ⟨10.2147/IJN.S179290⟩
International Journal of Nanomedicine, 2018, 13, pp.6677-6688. ⟨10.2147/IJN.S179290⟩
International Journal of Nanomedicine, Dove Medical Press, 2018, 13, pp.6677-6688. ⟨10.2147/IJN.S179290⟩
International Journal of Nanomedicine, 2018, 13, pp.6677-6688. ⟨10.2147/IJN.S179290⟩
Anne Rodallec,1 Guillaume Sicard,1 Sarah Giacometti,1 Manon Carré,1 Bertrand Pourroy,2 Fanny Bouquet,3 Ariel Savina,3 Bruno Lacarelle,1 Joseph Ciccolini,1 Raphaelle Fanciullino1 1SMARTc Unit, Laboratory of Pharmacokinetics and Toxicology UFR Pharmac
Autor:
Bernadett Szabados, Mariano Ponz-Sarvise, Robson Machado, Diego Saldana, Edward Ernest Kadel, Romain Banchereau, Fanny Bouquet, Thomas Powles, Carsten Schroeder
Publikováno v:
Journal of Clinical Oncology. 40:548-548
548 Background: Real-world data (RWD) linking clinical outcomes with comprehensive genomic profiling (CGP) may enable identification of biomarkers to guide treatment selection and stratification in future trials. The primary objective was to characte
Autor:
Sylvie Sauvaigo, Julien Girard, Marie-Thérèse Leccia, Sarah Libert, Manel Benkhiat, Stéphane Mouret, Florence de Fraipont, Fanny Bouquet, Caroline Aspord, Florian Braisaz
Melanoma, the most serious form of skin cancer, frequently involves the dysregulation of key signaling pathways. Treatment strategies presently target the MAPK/ERK pathway, which is overactive in melanomas due in part to BRAF and NRAS mutations, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dd652f8764bc452c02cc5fed3ce0989
https://doi.org/10.1101/2020.04.29.067900
https://doi.org/10.1101/2020.04.29.067900
Autor:
Bruno Lacarelle, Raphaelle Fanciullino, Guillaume Sicard, Anne Rodallec, Margaux Valette, Joseph Ciccolini, Manon Carré, Sarah Giacometti, Thomas Maia, Fanny Bouquet, Ariel Savina
Publikováno v:
Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2020, 31 (5), pp.463-472. ⟨10.1097/CAD.0000000000000878⟩
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2020, 31 (5), pp.463-472. ⟨10.1097/CAD.0000000000000878⟩
Nanoparticles have been used for decades in breast cancer. More recently, anti-human epidermal receptor 2 (Her2) immunoliposomes are of rising interest. However, recent studies have questioned the actual relevance of using anti-Her2 antibodies to imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632c8ea0763b7b47d56a8c69fc218a30
https://hal.archives-ouvertes.fr/hal-03464972
https://hal.archives-ouvertes.fr/hal-03464972
Autor:
Fanny Bouquet, Sarah Giacometti, Joseph Ciccolini, Bruno Lacarelle, Ariel Savina, Anne Rodallec, Jean Michel Brunel, Raphaelle Fanciullino, Helene Maccario, Florian Correard, Eric Mas, Caroline Orneto
Publikováno v:
International Journal of Nanomedicine
International Journal of Nanomedicine, Dove Medical Press, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩
International Journal of Nanomedicine, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩
International Journal of Nanomedicine, Dove Medical Press, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩
International Journal of Nanomedicine, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩
Background Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity balance of this doublet by improving drug trafficking and delivery to tumors. Thi
Autor:
François M. Vallette, Marie-Pierre Joalland, Didier Decaudin, Mathilde Cabart, Jaafar Bennouna, Fanny Bouquet, Ariel Savina, Judith Raimbourg, Ludmilla de Plater, Lisenn Lalier
Publikováno v:
Molecular Cancer Therapeutics. 16:1634-1644
The benefit of EGFR–TKI in non–small cell lung cancer has been demonstrated in mutant EGFR tumors as first-line treatment but the benefit in wild-type EGFR tumors is marginal as well as restricted to maintenance therapy in pretreated patients. Th
Autor:
Eric Pasmant, Brigitte Dréno, Houssem Benlalam, Marina Colombo, Antoine Toubert, Emmanuelle Fourmentraux-Neves, Frédéric Vély, Florence Faure, Fanny Bouquet, Ariel Savina, Marie-Françoise Avril, Sylvie Rusakiewicz, Laurence Zitvogel, Meriem Messaoudene, Anne Caignard, Alexandra Frazao, Eric Vivier
Publikováno v:
Cancer Immunology Research
Cancer Immunology Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩
Cancer Immunology Research, American Association for Cancer Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩
Cancer Immunology Research-Cancer Immunol Res
Cancer Immunology Research-Cancer Immunol Res, Philadelphia, PA : American Association for Cancer Research, [2013]-, 2017, 5 (7), pp.582-593. 〈10.1158/2326-6066.CIR-16-0380〉
Cancer Immunology Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩
Cancer Immunology Research, American Association for Cancer Research, 2017, 5 (7), pp.582-593. ⟨10.1158/2326-6066.CIR-16-0380⟩
Cancer Immunology Research-Cancer Immunol Res
Cancer Immunology Research-Cancer Immunol Res, Philadelphia, PA : American Association for Cancer Research, [2013]-, 2017, 5 (7), pp.582-593. 〈10.1158/2326-6066.CIR-16-0380〉
Over 60% of human melanoma tumors bear a mutation in the BRAF gene. The most frequent mutation is a substitution at codon 600 (V600E), leading to a constitutively active BRAF and overactivation of the MAPK pathway. Patients harboring mutated BRAF res
Autor:
S. Mourah, S. Nikolaev, Nicole Basset-Seguin, Fanny Bouquet, Meriem Ighilahriz, M. Benfodda, Hayley J. Sharpe, Nicolas Dumaz, Marisa Battistella, Nadem Soufir, Ariel Savina
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 33
Autor:
Anne Rodallec, Guillaume Sicard, Sarah Giacometti, Manon Carré, Bertrand Pourroy, Fanny Bouquet, Ariel Savina, Bruno Lacarelle, Joseph Ciccolini, Raphaelle Fanciullino
Publikováno v:
International Journal of Nanomedicine
Purpose Nanoparticles are of rising interest in cancer research, but in vitro canonical cell monolayer models are not suitable to evaluate their efficacy when prototyping candidates. Here, we developed three-dimensional (3D) spheroid models to test t
Autor:
Louisa Barré, Fanny Bouquet, Aurélie N. Gérault, Ariel Savina, Elodie A. Pérès, Aurélien Corroyer-Dulmont, Eric T. MacKenzie, Myriam Bernaudin, Didier Divoux, Edwige Petit, Jérôme Toutain, M Ibazizène, Samuel Valable
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2016, 43 (4), pp.682-694. 〈10.1007/s00259-015-3225-0〉
European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 (4), pp.682-694. ⟨10.1007/s00259-015-3225-0⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2016, 43 (4), pp.682-694. ⟨10.1007/s00259-015-3225-0⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2016, 43 (4), pp.682-694. 〈10.1007/s00259-015-3225-0〉
European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 (4), pp.682-694. ⟨10.1007/s00259-015-3225-0⟩
European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2016, 43 (4), pp.682-694. ⟨10.1007/s00259-015-3225-0⟩
International audience; PURPOSE:The primary objective of this study was to compare the ability of PET and MRI biomarkers to predict treatment efficacy in a preclinical model of recurrent glioblastoma multiforme.METHODS:MRI (anatomical, diffusion, vas